Clinical trial • Not applicable • Musculoskeletal
OXYGEN for Acute hamstring injury
Not applicable trial of OXYGEN for Acute hamstring injury. open-label, historical control group (standard care).. 50 participants.
Overview
- Trial Therapeutic Area
- Musculoskeletal
- Trial Disease
- Acute hamstring injury
- Trial Stage
- Not applicable
- Drug Modality
- Other
Key dates
- Initial CTIS Submission Date
- 18-12-2023
- First CTIS Authorization Date
- 22-04-2024
Trial design
open-label, historical control group (standard care). Not applicable trial in Netherlands.
- Open Label
- Yes
- Comparator
- Historical control group (standard care).
- Real World Control
- Yes
- Target Sample Size
- 50
Eligibility
Recruits 50 No vulnerable population selected. Participants must provide signed informed consent. Eligible ages 18-65. No assent procedures or special consent provisions for minors described..
- Pregnancy Exclusion
- pregnancy or claustrophobia
- Vulnerable Population
- No vulnerable population selected. Participants must provide signed informed consent. Eligible ages 18-65. No assent procedures or special consent provisions for minors described.
Inclusion criteria
- {"criterion_text":"- The participant is 18-65 years old\n- The participant has a clinical diagnosis of an acute hamstring injury ≤7 days old, defined as: a) Anamnestic acute injury; b) Anamnestic pain in the posterior thigh; c) Localized pain during plapation of the hamstring muscle; d) Localized pain during passive straight leg raise test e) Increased pain during isometric contraction\n- The participant is able to start HBOT ≤7 days of injury\n- Signed informed consent"}
Exclusion criteria
- {"criterion_text":"- There are contra-indications for hyperbaric oxygen therapy: Smoking or quit smoking <3 months prior to injury, a previous spontaneous pneumothorax, a ICD or pacemaker not compatible with hyperbaric pressure, Current or recent (6 months) use of cytostatics, Unable to perform a Vasalva manoeuvre to pressurize the middle ear, pregnancy or claustrophobia\n- The participant does not have the intention to return to full sporting / -duty activities.\n- The cause of the hamstring injury is an extrisic trauma on the posterior thigh\n- The participant has a chronic injury (>2 months), defined as reccurent pain or tenderness of the hamstring muscles.\n- The current injury is a hamstring re-injury, defined as: A repeat injury <2 months following Return to play / return to full unrestricted duty from a previous hamstring injury;\n- The current injury is a complete proximal tendon avulsion (grade III hamstring injury)\n- There are other, concurrent injuries inhibiting rehabilitation\n- There are contra-indications for MRI: Incompatible pacemakers/ICD's, pregnancy or claustrophobia."}
Endpoints
Primary endpoints
- {"endpoint_text":"- Time needed to return to play (days) for athletes or time needed to return to full unrestricted duty (days) for military personnel.","definition_or_measurement_approach":"Measured as time in days to return to play (RTP) for athletes or time in days to return to full unrestricted duty for military personnel."}
Secondary endpoints
- {"endpoint_text":"- Patient reported hamstring scores: Tenger activity score, Functional assessment scale for acute hamstring injuries and psychological readiness.\n- Maximum and mean pain scores (0-10) assessed with the visual analog scale, at injury, at rest and during sprinting\n- Physical examination including: - Palpation: Location and dimension of painful area/lesion, presence of hematoma or – swelling o Pain with isometric contraction - Hamstring flexibility tests: Passive straight leg raise, Active knee extension test. - Hamstring isometric strength (Hand hold dynamometer)\n- MRI derived parameters: Aspect of the injury on T1 and T2- weighted images scored by a radiologist using a standardized form.\n- Number of re-injury at 2- and 12 months following return to play/ return to full unrestricted duty.\n- Number of (serious)adverse events from inclusion to ≤7 days following the last hyperbaric oxygen treatment session.","definition_or_measurement_approach":"Patient-reported outcomes: validated scores (Tenger activity score, Functional assessment scale, psychological readiness). Pain: VAS 0-10 at injury, rest and during sprinting. Physical exam: palpation, pain with isometric contraction, PSLR and AKE flexibility tests, isometric strength measured with handheld dynamometer. MRI: radiologist scoring of T1/T2 images using standardized form. Re-injury: count of re-injuries at 2 and 12 months following RTP. Safety: count of (serious) adverse events from inclusion to ≤7 days after last HBOT."}
Recruitment
- Planned Sample Size
- 50
- Recruitment Window Months
- 72
- Consent Approach
- Signed informed consent is required from participants. Eligible participants are adults 18-65. No assent procedures for minors described. Study documents include Dutch translations of key text; specific consent document languages not detailed.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 50
Netherlands
- Earliest CTIS Part Ii Submission Date
- 08-04-2024
- Latest Decision Or Authorization Date
- 22-04-2024
- Processing Time Days
- 14
- Number Of Sites
- 1
- Number Of Participants
- 50
Sites
- Site Name
- Amsterdam UMC
- Department Name
- Orthopedic Surgery & Sports medicine
- Principal Investigator Name
- J.L. Tol
- Principal Investigator Email
- ctis@amsterdamumc.nl
- Contact Person Name
- J.L. Tol
- Contact Person Email
- ctis@amsterdamumc.nl
Sponsor
Primary sponsor
- Full Name
- Amsterdam UMC
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Third parties
- {"country":"","full_name":"ZonMW","duties_or_roles":"Monetary support","organisation_type":""}
- {"country":"","full_name":"NOC-NSF","duties_or_roles":"Monetary support","organisation_type":""}
Investigational products
- Investigational Product Name
- Conoxia, 100% v/v, medicinaal gas, samengeperst
- Active Substance
- OXYGEN
- Modality
- Other
- Routes Of Administration
- INHALATION
- Route
- INHALATION
- Authorisation Status
- Authorised (marketing authorisation RVG 30355)
- Maximum Dose
- maxTotalDoseAmount 12100 l
- Investigational Product Name
- Conoxia® Vloeibaar, 100% v/v, medicinaal gas, cryogeen
- Active Substance
- OXYGEN
- Modality
- Other
- Routes Of Administration
- INHALATION
- Route
- INHALATION
- Authorisation Status
- Authorised (marketing authorisation RVG 100211)
- Maximum Dose
- maxTotalDoseAmount 12100 l
Related trials
Other published trials that may interest you.